Presented Posters

QR CODE POSTER ID POSTER
0116 P1.1. Central effects of botulinum Toxin A Recovery of spinal inhibition after botulinum toxin A in stroke patients
0050 P1.2. Using the muscle force test in the monkey to measure biological activity of botulinum neurotoxins
0013 P1.3. Validation of the “BINACLE” (Binding and Cleavage) Assay for the In Vitro Safety Testing of Tetanus Vaccines
0085 P1.7. Botulinum Neurotoxin Type A–Cleaved SNAP25 Is Confined to Primary Motor Neurons and Localized on the Plasma Membrane Following Intramuscular Toxin Injection
0117 P1.8. BIOLOGICAL TOXINS DETECTION: A RAPID DIAGNOSIS IN AN EMERGENCY RESPONSE
0061 P1.10. Augmentation of the catalytic activity of Botulinum Neurotoxin Type B does not result in increased potency in physiological systems
0064 P1.11. HPLC analysis of recombinant Botulinum neurotoxins: expanding the analytical toolbox
0032 P1.12. Use of high-content imaging in botulinum toxin research
0063 P1.13. Mechanisms of intestinal absorption of botulinum neurotoxin comples
0046 P1.14. Purification and characterisation of recombinant botulinum neurotoxin serotype FA, also known as serotype H
0040 P1.16. An evaluation of the cGMP manufacturing process economics and high-throughput characterisation of Targeted Secretion Inhibitors
0041 P1.17. Recombinant Botulinum neurotoxin serotype A1 (SXN102342): protein engineering and process development
0019 P1.20. rBoNT/A mutants with polypeptide extension show different kinetic properties
0049 P1.21. SXN102342, a novel, recombinant botulinum neurotoxin type A1: in vivo characterization
0037 P1.24. Rational modification of botulinum neurotoxin by directed scanning mutagenesis
0110 P1.25. THE FIRST CASE OF TYPE F BOTULISM, IN PORTUGAL
0020 P1.26. Light-chain-modified rBoNT/A mutants with improved stability
0048 P1.27. An innovative solution to the unique challenges in manufacturing recombinant botulinum neurotoxins
0038 P1.28. Human and mouse isolated bladder preparations are not equally affected by botulinum neurotoxin serotypes A and B
0043 P1.32. SNARE complexes mediate TNFα-induced co-trafficking of TRPV1 and TRPA1 on pain peptide-containing vesicles to the surface of sensory neurons
0021 P1.34. Design of modified botulinum toxin A variants with a shorter persistence of paralysis
0022 P1.35. Properties of a chimeric BoNT/A1–A4
0109 P1.36. NT401 (FasTox): a novel, rapid, and short-acting modified botulinum neurotoxin
0033 P1.37. Informed manufacturing process development of a recombinant botulinum neurotoxin through the use of a sensitive and reproducible sandwich ELISA
0121 P1.39. CENTRAL IMMEDIATE EFFECT OF BOTULINUM TOXIN THERAPY OF GENERALIZED SPASTICITY
0094 P1.46. GANGLIOSIDE RECEPTOR RECOGNITION BY BOTULINUM NEUROTOXIN A
0093 P2.1. STRUCTURAL CHANGES OF CORTICAL THICKNESS AFTER BOTULINUM TOXIN TREATMENT (BONT) ASSOCIATED TO MOTOR RE-LEARNING TECHNIQUES (MRT) IN PATIENTS WITH CERVICAL DYSTONIA (CD). A LONGITUDINAL NEUROIMAGING STUDY.
0086 P2.3. DURATION OF THE CLINICAL EFFECT OF BOTULINUM TOXIN IN FOCAL DYSTONIAS
0002 P2.6. Sensory Trick: Infiltration of its Trigger Point with Botulinum Neurotoxin in Cervical Dystonia
0008 P2.7. Predictors of OnabotulinumtoxinA Treatment Response in Patients with Cervical Dystonia
0024 P2.8. Treatment of camptocormia in patients with Parkinson’s disease by injecting incobotulinumtoxin A (Xeomin®)
0072 P2.9. Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared With Placebo in Adult Patients With Cervical Dystonia
0045 P2.12. PRETARSAL BLEPHAROSPASM: CLINICAL, ELECTROMIOGRAPHIC FEATURES AND LONG TERM TREATMENT WITH BOTULINUM TOXIN
0065 P2.14. Clinical Characteristics of Oromandibular Dystonia: a Multicenter Review of 201 Cases
0096 P2.15. Comparison of Methodology, Patient Characteristics, and Treatment Results from ANCHOR-CD (AbobotulinumtoxinA Neurotoxin: Clinical and Health Economics Outcomes Registry in Cervical Dystonia) and Other Registry Studies of Bolulinum Toxin Type A in Cervical Dystonia
0026 P2.16. TRANSORAL ADMINISTRATION OF INCOBOTULINUMTOXIN A FOR THE MANAGEMENT OF LARYNGEAL DYSTONIA
0111 P2.18. A randomized, double-blind, placebo-controlled trial on the efficacy and safety of incobotulinumtoxinA (Inco/A) for essential tremor using kinematics-guided clinical decision support
0010 P3.1. CONTRAST-ENHANCED ULTRASOUND ASSESSMENT OF THE MICROCIRCULATION OF SPASTIC CALF MUSCLES PRIOR TO BOTULINUM TOXIN TYPE A INJECTION IN PATIENTS WITH LONG-STANDING LOWER LIMB SPASTICITY (INITIAL EXPERIENCE)
0014 P3.2. INTEGRATED MANAGEMENT OF UPPER-LIMB SPASTICITY WITH BOTULINUM TOXIN TYPE A INJECTIONS AND KINESIO TAPING
0104 P3.3. Efficacy of incobotulinumtoxinA (Xeomin®) in treatment of lower-limb spasticity, including pes equinovarus, in adults
0126 P3.5. OUTCOME OF A MULTILEVEL BoNTA TREATMENT, WHEN INCLUDING SHOULDER MUSCLES, USING PATIENT-CENTERED GOAL ATTAINMENT
0127 P3.6. RELEVANCE AND IMPACT OF INCLUDING SHOULDER MUSCLES IN TREATMENT OF POST-STROKE UPPER LIMB SPASTICITY
0113 P3.7. ARE THERE DIFFERENCES IN MOST FREQUENTLY INJECTED MUSCLES IN UPPER, LOWER AND UPPER + LOWER LIMBS, REGARDING THE TREATMENT GOAL AREAS? AN OVERVIEW OF REAL-LIFE CLINICAL PRACTICE IN A REFERENCE SPASTICITY CLINIC
0025 P3.9. EFFICACY AND SAFETY OF INCOBOTULINUMTOXINA (XEOMIN®) IN THE TREATMENT OF SEVERE MUSCLE SPASTICITY FOLLOWING TRAUMATIC BRAIN INJURY: A CASE REPORT
0098 P3.10. Botulinum toxin treatment for spasticity: clinical experience with changing from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®)
0051 P3.11. Correlations between reduced spasticity, goal attainment and global assessment of benefits in patients with upper limb spasticity treated with botulinum toxin A
0097 P3.12. Switching botulinum toxin formulations from onabotulinumtoxinA (Botox®) to incobotulinumtoxinA (Xeomin®): experience from a spasticity outpatient clinic
0073 P3.13. Phase 3 Trial to Evaluate AbobotulinumtoxinA (Dysport®) Injections in Children with Upper Limb Spasticity due to Cerebral Palsy: A Study Design
0047 P3.14. AbobotulinumtoxinA (Dysport®) injection doses per muscle in paediatric patients with lower limb spasticity
0114 P3.15. Time to retreatment after abobotulinumtoxinA (Dysport®) injections in children with dynamic equinus foot deformity
0066 P3.17. A DESCRIPTIVE ANALYSIS OF TREATMENT GOALS IN A LARGE POST-STROKE OUTPATIENT POPULATION REFLECTED BY THE ROUTINE PRACTICE OF A REFERENCE SPASTICITY CLINIC
0088 P3.19. EFFECTIVENESS OF BOTULINUM TOXIN TYPE A (BONT-A) IN LONG-TERM TREATMENT OF HEREDITARY SPASTIC PARAPLEGIA IN CHILDREN: REVIEW OF A SERIES OF 63 CASES
0074 P3.21. IS FUNCTIONAL IMPROVEMENT THE SAME IN STROKE PATIENTS TREATED WITH BOTULINUM TOXIN IN UPPER LIMB ONLY VS A TYPICAL POSTSTROKE INPATIENT POPULATION IN A NEUROREHABILITATION SERVICE?
0076 P3.22. POSTSTROKE UPPER LIMB SPASTICITY TREATMENT INCLUDING BOTULINUM TOXIN IN AN INPATIENT POST-ACUTE REHABILITATION PROGRAM: HOW ARE WE DOING IT?
0081 P3.23. TREATMENT PROGRAMS INCLUDING BOTULINUM TOXIN, TREATMENT GOALS, AND GOAL ACHIEVMENT FOR POSTSTROKE SPASTICITY: DOES TIME MATTER?
0053 P3.24. Duration of effect of abobotulinumtoxinA (Dysport®) in adult patients with lower limb spasticity post stroke or traumatic brain injury
0054 P3.25. Duration of effect of abobotulinumtoxinA (Dysport®) in adult patients with upper limb spasticity (ULS) post stroke or traumatic brain injury
0099 P3.25. Sustained incobotulinumtoxinA (Xeomin®) efficacy in upper-limb post-stroke spasticity over 48 weeks in a Phase 3, placebo-controlled study with an open-label extension
0052 P3.26. Improvement of active movement and function in adults with chronic spastic paresis following repeated treatment with abobotulinumtoxinA (Dysport®)
0100 P3.27. SPAsticity in PractiCE (SPACE) – an international, observational study of botulinum toxin type A in spasticity
0036 P3.28. Effectiveness and safety assessment of IncobotulinumtoxinA (XEOMIN®) injections in the lower-limb muscles of young, low-weight children with cerebral palsy
0082 P3.29. BOTULINUM TOXIN TYPE A – DOSES FOR 3 DIFFERENT FORMULATIONS: A REAL-LIFE PRACTICE EXPERIENCE IN POSTSTROKE SPASTICITY TREATMENT
0055 P3.30. Relationship between abobotulinumtoxinA injections into shoulder muscles and patient-centred primary goal selection and achievement: sub-analyses from the Upper Limb International Spasticity (ULIS)-II Study
0075 P3.31. THE IMPACT ON GAIT FUNCTIONALITY OF UPPER LIMB BOTULINUM TOXIN TREATMENT WITHIN AN INPATIENT REHABILITATION PROGRAM
0044 P3.32. INFLUENCE OF THE TIME INTERVAL BETWEEN INJECTIONS ON THE EFFICACY OF INCOBOTULINUMTOXINA (XEOMIN) FOR UPPER LIMB SPASTICITY: A PRELIMINARY STUDY
0108 P3.33. Duration of treatment effect of incobotulinumtoxinA (Xeomin®) in upper-limb spasticity
0106 P3.34. IncobotulinumtoxinA (Xeomin®) sustainably improves upper-limb spasticity – pooled analysis of two Phase 3 trials
0056 P3.36. A comparison of goal selection and achievement according to patient sex in the Upper Limb International Spasticity (ULIS)-II study
0016 P3.37. ANALYSIS OF TOTAL DOSAGES AND INTERVALS BETWEEN THE REPEATED ABOBOTULINUMTOXIN A INJECTIONS IN CHILDREN WITH SPASTIC CEREBRAL PALSY: MULTICENTRAL RUSSIAN STUDY
0017 P3.38. EVALUATION OF GOALS FOR BOTULINUM TOXIN TREATMENT DIRECTED TO POST STROKE SPASTICITY DURING 10 INJECTIONS
0115 P3.39. THERAPEUTIC BENEFIT OF BOTULINUM TOXIN A FOR SPASTICITY OF THE TRICEPS SURAE IN PATIENTS WITH MULTIPLE SCLEROSIS: AN OBSERVATIONAL STUDY ON GAIT SPATIOTEMPORAL PARAMETERS
0028 P3.40. CLINICAL PRACTICE WITH INCOBOTULINUMTOXINA (XEOMIN®) IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSY
0027 P3.41. EFFECTIVENESS AND PATIENT SATISFACTION WITH INCOBOTULINUMTOXIN A (XEOMIN®) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN MULTIPLE SCLEROSIS
0057 P3.42. A comparison of goal selection and achievement between botulinum toxin A (BoNT-A) naïve and non-naïve patients in the Upper Limb International Spasticity (ULIS)-II study
0009 P3.43. Botulinum neurotoxin injection techniques for the treatment of limb spasticity: a systematic review
0007 P3.44. Impact of Early Intervention With OnabotulinumtoxinA Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
0112 P3.45. DEFINING PATIENT-CENTRED GOALS IN BOTULINUM TOXIN POST–STROKE SPASTICITY DO TREATED REGIONS MATTER?
0077 P3.46. HOW WE MANAGE POST-STROKE SPASTICITY IN OUTPATIENT CLINICS: 16 YEAR EXPERIENCE OF A REFERENCE CENTER
0034 P3.47. An international, multicenter, prospective, randomized, evaluator-blinded study comparing different botulinum toxin injection strategies for treatment of upper limb spasticity
0103 P3.48. Long-term effects of high doses of incobotulinumtoxinA (Xeomin®) for treatment of spasticity
0058 P3.50. Baseline characteristics of patients from a pilot study to assess the effect of early use of abobotulinumtoxin-A (Dysport®) in spasticity progression post stroke
0067 P3.52. Assessment of botulinum toxin treatment in pediatric cerebral palsy patients in the United States managed Medicaid population
0118 P3.53. BOTULINUM TOXIN AND MIRROR THERAPY: A NEW APPROACH FOR POSTSTROKE SPASTICITY
0102 P3.54. Increasing doses of incobotulinumtoxinA (Xeomin®; 400–800 U) improve the functional impact of upper-limb spasticity
0089 P3.55. FLEXIBLE INTERVALS FOR BOTULINUM TOXIN A INJECTIONS IN DISABLING SPASTICITY
0059 P3.56. Integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: methodology for ULIS-III and initial goal-setting data
0042 P3.57. Improvement in poststroke upper limb spasticity patterns after treatment with Botulinum toxin A: A prospective observational study
0105 P3.58. Efficacy of incobotulinumtoxinA (Xeomin®) in the treatment of shoulder spasticity due to cerebral causes
0101 P3.59. Prospective, single-arm, dose-titration study of incobotulinumtoxinA (Xeomin®; up to 800 U) for treatment of upper- and lower-limb spasticity
0091 P3.60. COHORT OF POST STROKE SPASTIC HEMIPLEGIC PATIENTS USING BOTULINUM TOXIN TYPE A FROM 2004 TO 2016
0078 P3.61. BOTULINUM TOXIN TREATMENT FOR POST STROKE SPASTICITY: DO THE GOALS OF TREATMENT CHANGE OVER TIME
0092 P3.62. Improvement of spasticity following abobotulinumtoxinA (Dysport®) injections in shoulder muscles in hemiparetic patients with upper limb spasticity – Sub-analysis of a prospective, long-term, open-label study with single and repeated injection cycles
0071 P5.2. Safety and Tolerability of OnabotulinumtoxinA in the Treatment of Facial Lines: Statistical Meta-analysis of Pooled Data From Global Registration Studies of Treatment of Crow’s Feet Lines and Glabellar Lines in More Than 3900 Participants
0068 P5.3. OnabotulinumtoxinA in the Treatment of Crow’s Feet Lines in Japanese Subjects
0070 P5.4. Safety and Efficacy of OnabotulinumtoxinA in the Treatment of Crow’s Feet Lines and Glabellar Lines in Japanese Subjects
0069 P5.5. Safety and Efficacy of OnabotulinumtoxinA for the Treatment of Crow’s Feet Lines in Chinese Subjects
0001 P6.1. Anatomical look into OnabotulinumtoxinA injection for chronic migraine headache
0004 P6.2. Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
0011 P6.3. EFFICACY OF FLEXIBLE INCOBOTULINUMTOXINA TREATMENT INTERVALS IN A PATIENT WITH MYOFASCIAL PAIN IN UPPER CROSS SYNDROME
0035 P6.4. Results of a New Botox Injection Paradigm for Treatment of Migraines: Anatomical, Regional, and Targeted (ART)
0005 P6.5. OnabotulinumtoxinA for Chronic Migraine in Korea: 1-Month Post-Marketing Surveillance and Phase 4 Trial Results
0006 P6.7. Real-World Utilization and Safety of OnabotulinumtoxinA for Chronic Migraine from an Observational Study in the European Union
0030 P6.8. Administration of Neurotoxin-Disport as principal new approach to therapy of complicated forms of migraine
0083 P6.9. Botulinum Toxin Type A Infiltration for Primary Headache Syndrome Post-Intracerebral Hemorrhage. A Case Report
0015 P6.10. Long-term effficacy of ultrasound-guided injection of incobotulinumtoxinA (XEOMIN®) in piriformis syndrome
0012 P6.11. An integrated approach to the treatment of temporo-mandibular disorder with severe pain syndrome.
0090 P6.12. ROLE OF CORTICAL EXCITABILITY IN CHRONIC MIGRAINE PREVENTION: A STUDY DESIGN FOR A RANDOMIZED OPEN-LABEL TRIAL
0003 P7.1. INCOBOTULINUMTOXINA (XEOMIN) TREATMENT FOR THE CORRECTION OF MIMIC MUSCLE FUNCTION AFTER FACIAL NERVE INJURY
0023 P7.2. SKETCHING VIDEO GRABS FRAMES TO ASSESS GAIT IMPROVEMENT
0125 P7.3. BOTULINUM TOXIN B IN THE TREATMENT OF POSTMENOPAUSAL CRANIOFACIAL HYPERHIDROSIS
0018 P7.9. A Region Specific Technique To Quantify The Degree of Botulinum Muscle Diffusion Using Magnetic Resonance Imaging
0060 P7.10. ABOBOTULINUM TOXIN-A PROSPECTIVE RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY FOR DEGENERATIVE COXARTHROSIS
0107 P7.12. Efficacy of a 4:1 dose ratio in patients switching botulinum toxin formulation from abobotulinumtoxinA to incobotulinumtoxinA
0087 P7.13. BOTULINUM TOXIN INJECTIONS CAN PREVENT EARLY RELAPSE AFTER GIANT ABDOMINAL WALL SURGERY
0039 P7.17. An innovative international educational network to improve physicians’ current management practices for cervical dystonia and spasticity
0062 P7.18. Practical Management of Flu-like Symptoms Among Patients Receiving Botulinum Toxin Injections
0031 P7.19. BOTULINUM TOXIN AND ANTICHOLINERGICS IN THE TREATMENT OF COMPENSATORY HYPERHIDROSIS AFTER SYMPATHECTOMY
0123 P7.19. BOTULINUM TOXIN AND ANTICHOLINERGICS IN THE TREATMENT OF COMPENSATORY HYPERHIDROSIS AFTER SYMPATHECTOMY
0122 P7.22. EFFECT OF INCOBOTULINUM TOXIN-A (XEOMIN®) FOR THE TREATMENT OF OBSTRUCTIVE AND FUNCTIONAL EPIPHORA: A SHORT-TERM PILOT STUDY
0124 P7.23. HYPERHIDROSIS IN CHILDREN: A RETROSPECTIVE STUDY DESCRIBING SYMPTOMS, CONSEQUENCES, AND TREATMENT WITH BOTULINUM TOXIN TYPES A AND B
0029 P7.24. TEMPOROMANDIBULAR DISORDERS TREATED SUCCESSFULLY WITH INCOBOTULINUMTOXINA
0095 P7.28. Sensitivity of the extensor digitorum brevis and Minor’s starch-iodine tests at detecting dose-effects of Dysport® in male healthy volunteers
0084 P7.30. Two-step Approach with OnabotulinumtoxinA: Intradermal & Intramuscular Infiltrations for T8-T12 Chronic Post Herpetic Neuralgia: A Case Report